AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35713888
Drug: Baroreflex activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baroreflex activation therapy (BAT) + guideline-directed medical therapy (GDMT)
Trial: 38773653
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (normal saline)
Trial: 35123401
Drug: Basmisanil 120
RxNorm normalized name: Basmisanil
DrugBank: Basmisanil (DB11877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basmisanil 120 mg BID
Trial: 35123401
Drug: Basmisanil 240
RxNorm normalized name: Basmisanil
DrugBank: Basmisanil (DB11877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basmisanil 240 mg BID
Trial: 35123401
Drug: Basmisanil (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basmisanil (both doses)
Trial: 33381933
Drug: DW‐7202 (capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DW‐7202 (capsule type)
Trial: 32069068
Drug: Driving pressure-limited
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Driving pressure-limited strategy (ventilated with volume-controlled or pressure-support modes, tidal volume titrated to 4-8 ml/kg of predicted body weight, aiming for a driving pressure of 10 cm H2O or the lowest possible)
Trial: 32069068
Drug: Conventional lung-protective
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional lung-protective ventilation strategy (ARDSNet protocol, tidal volume of 6 ml/kg PBW, adjustable to 4 ml/kg PBW if plateau pressure >30 cm H2O)
Trial: 32890016
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal oxygen (HFNO) at 10 l/min before sedation and 50 l/min during the procedure
Trial: 32890016
Drug: Conventional oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oxygen face mask at 10 l/min during the procedure
Trial: 35134988
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (brief counseling)
Trial: 35134988
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (sustained counseling plus smoking cessation medication)
Trial: 32358379
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined therapy
Trial: 32715917
Drug: Bevacizumab treatment
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab treatment with urine protein monitoring every other treatment
Trial: 32715917
Drug: Bevacizumab treatment
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab treatment with urine protein monitoring every third treatment
Trial: 33248880
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy (OIT) with rush immunotherapy for 2 weeks, followed by a gradual increase of cow's milk volume to 100 mL for 1 year.
Trial: 33847224
Drug: Misoprostol utilization
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol utilization not continued beyond 6 doses or 24 h
Trial: 35580191
Drug: Rivaroxaban (10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10mg once daily for 3 weeks starting 7±2 days after surgery)
Trial: 33185002
Drug: glimepiride 1
RxNorm normalized name: glimepiride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glimepiride 1 to 4 mg
Trial: 37019385
Drug: ivarmacitinib 2
RxNorm normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivarmacitinib 2 mg once daily
Trial: 37019385
Drug: ivarmacitinib 4
RxNorm normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivarmacitinib 4 mg once daily
Trial: 37019385
Drug: ivarmacitinib 8
RxNorm normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivarmacitinib 8 mg once daily
Trial: 32917556
Drug: GFF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFF MDI (18/9.6 μg)
Trial: 32852428
Drug: 595-nm Pulsed
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 595-nm Pulsed Dye Laser treatment (fluence 7.5 J/cm2, 3-ms pulse duration, no dynamic cooling, 10-mm spot size, 10% overlap between pulses, 2 stacked pulses)
Trial: 32852428
Drug: Sham/control treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham/control treatment
Trial: 32559817
Drug: Systemic treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic treatment (immune or targeted therapy)
Trial: 32559817
Drug: LDH >500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDH >500 U/L
Trial: 35674759
Drug: Probiotic capsules
RxNorm normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic capsules containing multi-strain at least 1.6×10^9 CFU/g bacteria
Trial: 32665035
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 300 mg
Trial: 32665035
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) (low or moderate dose)
Trial: 32674675
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg (R10)
Trial: 32674675
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg (R15)
Trial: 32674675
Drug: DAPT (aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT (aspirin 75 mg and clopidogrel 75 mg)
Trial: 32674675
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg (R10) and Rivaroxaban 15 mg (R15)
Trial: 32038628
Drug: Nadolol (β1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (β1 + β2‐AR antagonist)
Trial: 32038628
Drug: Bisoprolol (β1‐AR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (β1‐AR antagonist)
Trial: 32991794
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg mRNA-1273 vaccine
Trial: 32991794
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg mRNA-1273 vaccine
Trial: 32991794
Drug: mRNA-1273 vaccine
RxNorm normalized name: SARS-CoV-2 mRNA-1273 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 vaccine (both doses)
Trial: 36088426
Drug: Histology-tailored chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histology-tailored chemotherapy regimen
Trial: 35427481
Drug: EV71vac (aluminium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71vac (aluminium phosphate‐adjuvanted inactivated EV71 vaccine), administered as two doses via intramuscular injection 56 days apart, with a third booster dose for children aged 2-23 months on day 366.
Trial: 35427481
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered as two doses via intramuscular injection 56 days apart.
Trial: 35427481
Drug: EV71vac (aluminium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71vac (aluminium phosphate‐adjuvanted inactivated EV71 vaccine)
Trial: 32115719
Drug: HIV-1 genotypic
RxNorm normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1 genotypic characteristics and transmitted drug resistance surveillance
Trial: 34718635
Drug: 100 g,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g, 200 g, 300 g whole beetroot (BR)
Trial: 34718635
Drug: 200 g
RxNorm normalized name: PEG-200 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g whole beetroot (BR)
Trial: 34718635
Drug: 300 g
RxNorm normalized name: Zantac 300 GELdose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 g whole beetroot (BR)
Trial: 34718635
Drug: Potassium nitrate
RxNorm normalized name: Potassium Nitrate
DrugBank: Potassium (DB14500)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Potassium nitrate (1000 mg)
Trial: 33781913
Drug: ChAd63-KH vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAd63-KH vaccine (1 × 10^10 viral particles for adults, 7.5 × 10^10 viral particles for adults and adolescents)
Trial: 39253357
Drug: ChAd63-KH vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAd63-KH vaccine
Trial: 32806711
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of Leucine-Enriched Essential Amino Acids (LEAA)
Trial: 35178112
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MTT and RVP
Trial: 32790196
Drug: High-dose teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: High-dose teriparatide (40 μg)
Trial: 32790196
Drug: Standard-dose teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard-dose teriparatide (20 μg)
Trial: 33826563
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic Acid (TXA) at a new dosing regimen (10 mg/kg load, 5 mg/kg/h infusion)
Trial: 33003132
Drug: McGrath MAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: McGrath MAC (McG)
Trial: 32748570
Drug: Lafenta transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lafenta transdermal fentanyl patch (11.0 mg)
Trial: 35756957
Drug: Phase I
RxNorm normalized name: Nuvelle TS Phase I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I therapy alone
Trial: 34333190
Drug: Japanese cedar
RxNorm normalized name: Japanese cedar pollen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Japanese cedar pollen sublingual immunotherapy (SLIT) tablets (5000 Japanese Allergy Units)
Trial: 35345248
Drug: Potent P2Y12
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potent P2Y12 inhibitors
Trial: 33631141
Drug: Solriamfetol 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol 300 mg/d
Trial: 34191352
Drug: Solriamfetol 75
RxNorm normalized name: solriamfetol 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol 75 mg/d, 150 mg/d, 300 mg/d
Trial: 33631141
Drug: Solriamfetol 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol 37.5 mg/d
Trial: 33631141
Drug: Solriamfetol 75
RxNorm normalized name: solriamfetol 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol 75 mg/d
Trial: 33631141
Drug: Solriamfetol 150
RxNorm normalized name: solriamfetol 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol 150 mg/d
Trial: 36084494
Drug: Solriamfetol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol (all doses combined)
Trial: 33318635
Drug: AV-101 (1440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV-101 (1440 mg)
Trial: 33318635
Drug: AV-101 (720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV-101 (720 mg)
Trial: 33318635
Drug: AV-101 (720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV-101 (720 mg and 1440 mg)
Trial: 35358462
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice of next-generation hormonal drug
Trial: 32487213
Drug: Post-operative placebo
RxNorm normalized name: Sx1 Medicated Post-Operative System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative placebo therapy (ceftriaxone 2 g/24 h and metronidazole 1500 mg/24 h for 3 days)
Trial: 32487213
Drug: Post-operative antibiotic
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative antibiotic therapy (ceftriaxone 2 g/24 h and metronidazole 1500 mg/24 h for 3 days)
Trial: 32438531
Drug: Intermittent fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent fasting (IF) with 100% or 70% of calculated weekly energy requirements for 8 weeks
Trial: 36195542
Drug: Volanesorsen, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volanesorsen, 300 mg weekly for 16 weeks
Trial: 36195542
Drug: Volanesorsen, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volanesorsen, 300 mg weekly for 32-52 weeks
Trial: 34837510
Drug: High-dose 131I-mIBG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose 131I-mIBG therapy (666 MBq/kg)
Trial: 34837510
Drug: Single high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high-dose chemotherapy (HDC)
Trial: 32578488
Drug: Capsifen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsifen (200 mg × 1/day, 4 mg capsaicinoids/day)
Trial: 34972765
Drug: Benznidazole (BZN)
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole (BZN) and Nifurtimox (NFX) chemotherapy regimens
Trial: 32345375
Drug: Intervention program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention program consisting of detecting symptoms of mental illness, strengthening parenting skills using the Circle of Security Parenting program, supporting breastfeeding, and organizing treatment pathways.
Trial: 35575051
Drug: Fractional-dose IPV
RxNorm normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional-dose IPV (fIPV, one-fifth of IPV) - 1 dose
Trial: 35575051
Drug: Fractional-dose IPV
RxNorm normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional-dose IPV (fIPV, one-fifth of IPV) - 2 doses
Trial: 35575051
Drug: Full-dose IPV
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose IPV
Trial: 35575051
Drug: Full-dose IPV
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose IPV - 2 doses
Trial: 33609248
Drug: Venetoclax in
RxNorm normalized name: Product containing venetoclax in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax in combination with azacitidine
Trial: 33609248
Drug: Ongoing clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing clinical trials with low- and high-intensity therapies
Trial: 32448020
Drug: riluzole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: riluzole (50 mg)
Trial: 34800079
Drug: Patiromer (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patiromer (titrated up to a maximum of three packs/day, 8.4 g/pack)
Trial: 34563120
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality (VR) exercises based on Xbox Kinect, 2 sessions of 30-45 minutes weekly for 6 weeks
Trial: 37415648
Drug: Combined Therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Therapy (CT)
Trial: 32790066
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg glasdegib
Trial: 32790066
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg glasdegib
Trial: 35753072
Drug: High Intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Intensity Interval Training (HIIT) four times weekly (EX; n=20)
Trial: 32947383
Drug: Topical povidone-iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical povidone-iodine 10% plus levofloxacin 0.5% at 1 hour preoperatively
Trial: 33637837
Drug: Predictive algorithm
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictive algorithm guided treatment
Trial: 34616464
Drug: Melatonin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (3 mg) for two weeks at 10 PM
Trial: 34666693
Drug: UV irradiation
RxNorm normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV irradiation (half-body UV irradiation, twice weekly over 6 months at one standard erythema dose)
Trial: 33546739
Drug: Baricitinib (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib (4 mg once daily, can be reduced to 2 mg) for 5-7 days
Trial: 33546739
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (including antibiotics, thromboembolic prophylaxis, and possibly remdesivir)
Trial: 36071262
Drug: Metformin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin as an adjunct to antidepressants
Trial: 32044695
Drug: Balance specific
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balance specific physiotherapy (Motor Program Activating Therapy in Czech cohort and Sensory-motor Integration Training in Italian cohort)
Trial: 39717452
Drug: Corticosteroid (CS)
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid (CS) injection
Trial: 34459702
Drug: Rituximab 375
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2 every 8 weeks for 2 years (arm B)
Trial: 34243616
Drug: Intravenous fixed-dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fixed-dose combination (FDC) of acetaminophen 1000 mg + ibuprofen 300 mg administered 6-hourly as a 5 min infusion for 48 hours to 5 days
Trial: 32797236
Drug: Intranasal desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal desmopressin (40 μg)
Trial: 32043426
Drug: arthroscopic microfracture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: arthroscopic microfracture plus intra‐articular injection of HA and haMPCs
Trial: 32043426
Drug: arthroscopic microfracture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: arthroscopic microfracture and intra‐articular injection of HA
Trial: 32043426
Drug: arthroscopic microfracture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: arthroscopic microfracture group and normal saline injection
Trial: 34474267
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intravenous (IV) metoclopramide
Trial: 34474267
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg intravenous (IV) ketorolac
Trial: 616121600
Drug: Idebenone (Raxone)
DrugBank: Idebenone (DB09081)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Idebenone (Raxone) 150 mg tablets
Trial: 34557985
Drug: OTee HORSPLAY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTee HORSPLAY (occupational therapy in an equine environment) for 10 weeks
Trial: 34557985
Drug: OTee HORSPLAY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTee HORSPLAY (occupational therapy in an equine environment)
Trial: 34557985
Drug: Waitlist control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist control condition (occupational therapy in a garden)
Trial: 34006542
Drug: Morphine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (2 mg subcutaneous injection)
Trial: 36125055
Drug: Initial oral
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial oral antipsychotic (OAP) switched to PP after 9 months (OAP-PP)
Trial: 35698094
Drug: Weekly screening
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly screening + symptomatic testing
Trial: 33476593
Drug: Nivolumab (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (360 mg intravenously every 3 weeks) plus ipilimumab (1 mg/kg intravenously every 6 weeks) combined with histology-based, platinum doublet chemotherapy (intravenously every 3 weeks for two cycles)
Trial: 33476593
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab with two cycles of chemotherapy
Trial: 33476593
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (every 3 weeks for four cycles)
Trial: 32169403
Drug: Citalopram added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram added to clinician-determined antipsychotic treatment
Trial: 33721696
Drug: Inhaled iloprost
RxNorm normalized name: iloprost Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled iloprost (5.0 μg)
Trial: 32251031
Drug: Intrathecal Morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal Morphine
Trial: 32434243
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis with 160 mg trimethoprim combined with 800 mg sulfamethoxazole three times a week for 12 months (placebo-controlled double-blind study)